Indicators
Indicators
Value
Direction
MACD(12,26,9)
--
--
RSI(14)
--
--
STOCH(KDJ)(9,3,3)
--
--
ATR(14)
--
--
CCI(14)
--
--
Williams %R
--
--
TRIX(12,20)
--
--
StochRSI(14)
--
--
Mustang Bio Inc
MBIOView Detailed Chart
1.630USD
+0.300+22.61%
Close 04/23, 16:00（ET）Quotes delayed by 15 min
27.56KMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+22.61%
5 Days
0.00%
1 Month
0.00%
6 Months
0.00%
Year to Date
0.00%
1 Year
0.00%
View Detailed Chart
Agency Rating
No Data
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Neutral
Moving Average
Indicators
Value
Direction
MA5
--
--
MA10
--
--
MA20
--
--
MA50
--
--
MA100
--
--
MA200
--
--
News
More news coming soon, stay tuned...
Company
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating medical breakthroughs into potential cures for cancers and autoimmune diseases. The Company has partnered with medical institutions to advance the development of chimeric antigen receptor modified T cell (CAR T) therapies. Its pipeline is focused in two core areas: CAR T therapies for autoimmune diseases and hematologic malignancies and CAR T therapies for solid tumors. It is developing a CAR T therapy for hematologic malignancies and autoimmune diseases in partnership with Fred Hutchinson Cancer Center targeting CD20 and for solid tumors in partnership with City of Hope National Medical Center targeting IL13Ra2. It has also partnered with Nationwide Children’s Hospital for a herpes simplex virus type 1 oncolytic virus to enhance the activity of MB-101 for the treatment of patients with high-grade malignant brain tumors.
Company codeMBIO
CompanyMustang Bio Inc
CEODr. Manuel Litchman, M.D.
Websitehttps://www.mustangbio.com/
